The Public M&A and Life Sciences teams advised Blueprint Medicines Corporation (Nasdaq: BPMC) in its definitive agreement to be acquired by Sanofi (NASDAQ: SNY) for an upfront payment of $129.00 per share of Blueprint common stock in cash. Blueprint stockholders also will receive one non-tradeable contingent value right ("CVR") which will entitle the holder to receive two potential milestone payments of $2.00 and $4.00 per CVR for the achievement of certain development and regulatory milestones, respectively, for BLU-808. The total equity value of the transaction, including the potential CVR payment, represents approximately $9.5 billion on a fully diluted basis.
The transaction is subject to customary closing conditions, including the tender of a majority of shares of Blueprint common stock, the receipt of required regulatory approvals, and other customary conditions. Blueprint expects the transaction to close in the third quarter of 2025.
Blueprint Medicines Corporation is a global, fully integrated biopharmaceutical company that invents life-changing medicines. They seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Their approach begins by targeting the root causes of disease, using deep scientific knowledge in their core focus areas and drug discovery expertise across multiple therapeutic modalities. They have a track record of success with two approved medicines, including AYVAKIT/AYVAKYT (avapritinib) which we are bringing to patients with SM in the US and Europe. Leveraging their established research, development, and commercial capability and infrastructure, they aim to significantly scale their impact by advancing a broad pipeline of programs ranging from early science to advanced clinical trials in mast cell diseases and solid tumors. Blueprint Medicines Corporation is listed on NASDAQ: BPMC.
The Goodwin team was led by Stuart Cable, Lisa Haddad, Kingsley Taft, Danielle Lauzon, Sarah Solomon, Sarah Bock and James Ding and included Yifeng Yuan, Joseph Powers, Angela Kim, Candace Hagey, Yasin Akbari, Kate Riddle, Aisha Khan, Nikhil Shiva,Theresa Kavanaugh, Alexandra Haas, Jo-an Chen, Lauren Kidd,Miho Kaneko, Grace Wirth, Zoe Li,Paul Jin, Arman Oruc, Sarah Jordan, Anuj Ghai, Andrew Jensen, Arom Yun, Samuel Honnywill, Julie Tibbets, Heath Roosevelt Ingram, Avi Strauss, Javier Gonzalez Rivera, Jacqueline Klosek, Daniel Karelitz, Erika Pey, Deborah S. Birnbach, John Barker, Adam Slutsky, Justin C. Pierce, Gozde Guckaya, Kuwabo Mubyana, Jennifer Merrigan Fay, Lauren NuDelman, Nathan Brodeur, Kristopher Ring, Cecelia Lockner, Tris Cox, Nika Baghestani, and Marina Gibbs-Logue.
For additional details on the acquisition, please read the press release and coverage in The Wall Street Journal, Reuters and Bloomberg.